ALK-rearranged histiocytosis: Report of two cases with involvement of the central nervous system.
ALK-rearranged hystiocytosis
CNS
KIF5B-ALK fusion
cerebral lesion
spindle cell morphology
Journal
Neuropathology and applied neurobiology
ISSN: 1365-2990
Titre abrégé: Neuropathol Appl Neurobiol
Pays: England
ID NLM: 7609829
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
15
05
2021
received:
10
02
2021
accepted:
24
05
2021
pubmed:
29
5
2021
medline:
29
1
2022
entrez:
28
5
2021
Statut:
ppublish
Résumé
Histiocytoses are a heterogeneous group of localized or disseminated diseases. Clinical presentation and patients' outcome vary greatly, ranging from mild to life-threatening disorders. Rare cases of systemic or localized histiocytosis harboring ALK rearrangement have been reported. Two cases of CNS histiocytosis were thoroughly investigated by implementing multiple molecular tests, i.e. FISH, RT-qPCR, NGS analysis. In a 10-month old girl (patient #1), MRI showed two left hemispheric lesions and a right fronto-mesial lesion histologically consisting of a moderately cellular infiltrative proliferation, composed by CD68(PGM1)+/CD163+ spindle cells. ALK 5'/3'-imbalance and a KIF5B(exon 24)-ALK(exon 20) fusion were documented by RT-qPCR and NGS analysis, respectively. A subsequent CT scan showed multiple hepatic and pulmonary lesions. The patient was started on chemotherapy (vinblastine) associated to an ALK-inhibitor (Alectinib) with remarkable response. In a 11-year-old girl (patient #2), MRI showed a right frontal 1.5 cm lesion. Neuropathological examination revealed a histiocytic proliferation composed by medium sized CD68(PGM1)+/HLA-DR+ cells, showing moderate ALK1 positivity. ALK rearrangement and a KIF5B(exon 24)-ALK(exon 20) fusion were demonstrated also in this case. Subsequent CT, 18F-FDG-PET and MRI scans showed the presence of a single right femoral lesion, proved to be a fibrous cortical defect. In ALK-histiocytoses, CNS involvement may occur as part of a systemic disease or, rarely, as its only primary disease localization, which could remain otherwise asymptomatic. The diagnosis often relies on neuropathological examination of brain biopsy, which may pose a diagnostic challenge due to the variable histopathological features. An integrated histological and molecular approach in such cases is recommended.
Substances chimiques
Protein Kinase Inhibitors
0
ALK protein, human
EC 2.7.10.1
Anaplastic Lymphoma Kinase
EC 2.7.10.1
Receptor Protein-Tyrosine Kinases
EC 2.7.10.1
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
878-881Informations de copyright
© 2021 British Neuropathological Society.
Références
Chan JKC, Lamant L, Algar E, et al. ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy. Blood. 2008;112:2965-2968.
Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic Neoplasms. Cancer Discov. 2016;6:154-165.
Facchetti F, Pileri SA, Lorenzi L, et al. Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases. Virchows Arch. 2017;471:467-489.
Huang H, Gheorghe G, North PE, Suchi M. Expanding the phenotype of ALK-positive histiocytosis: a report of 2 cases. Pediatr Dev Pathol. 2018;21:449-455.
Chang KTE, Tay AZE, Kuick CH, et al. ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion. Mod Pathol. 2019;32:598-608.
Gupta GK, Xi L, Pack SD, et al. ALK-positive histiocytosis with KIF5B-ALK fusion in an adult female. Haematologica. 2019;104:e534-e536.
Kashima J, Yoshida M, Jimbo K, et al. ALK-positive histiocytosis of the breast: a clinicopathologic study highlighting spindle cell histology. Am J Surg Pathol. 2021;45(3):347-355.
Lucas C-H, Gilani A, Solomon DA, et al. ALK-positive histiocytosis with KIF5B-ALK fusion in the central nervous system. Acta Neuropathol. 2019;138:335-337.
Maruggi M, Malicki DM, Levy ML, Crawford JR. A novel KIF5B-ALK fusion in a child with an atypical central nervous system inflammatory myofibroblastic tumour. BMJ Case Rep. 2018;bcr2018226431.
Beardslee T, Lawson J Alectinib and Brigatinib: new second-generation ALK inhibitors for the treatment of non-small cell lung cancer. J Adv Pract Oncol. 2018;9:94-101.
Clarke M, Mackay A, Ismer B, et al. Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. Cancer Discov. 2020;10:942-963.